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Abstract
The effects of vaccine on postinfection outcomes, such as disease, death, and secondary transmission
to others, are important scientific and public health aspects of prophylactic vaccination. As a result,
evaluation of many vaccine effects condition on being infected. Conditioning on an event that occurs
posttreatment (in our case, infection subsequent to assignment to vaccine or control) can result in
selection bias. Moreover, because the set of individuals who would become infected if vaccinated is
likely not identical to the set of those who would become infected if given control, comparisons that
condition on infection do not have a causal interpretation. In this article we consider identifiability
and estimation of causal vaccine effects on binary postinfection outcomes. Using the principal
stratification framework, we define a postinfection causal vaccine efficacy estimand in individuals
who would be infected regardless of treatment assignment. The estimand is shown to be not
identifiable under the standard assumptions of the stable unit treatment value, monotonicity, and
independence of treatment assignment. Thus selection models are proposed that identify the causal
estimand. Closed-form maximum likelihood estimators (MLEs) are then derived under these models,
including those assuming maximum possible levels of positive and negative selection bias. These
results show the relations between the MLE of the causal estimand and two commonly used
estimators for vaccine effects on postinfection outcomes. For example, the usual intent-to-treat
estimator is shown to be an upper bound on the postinfection causal vaccine effect provided that the
magnitude of protection against infection is not too large. The methods are used to evaluate
postinfection vaccine effects in a clinical trial of a rotavirus vaccine candidate and in a field study
of a pertussis vaccine. Our results show that pertussis vaccination has a significant causal effect in
reducing disease severity.
Keywords
Causal inference; Infectious disease; Maximum likelihood; Principal stratification; Sensitivity
analysis
1. INTRODUCTION
The success of vaccines in reducing the burden of infectious diseases is one of the great
achievements in public health. The goal of vaccination is often not to prevent infection, but
rather to prevent or to ameliorate disease (Clements-Mann 1998). Therefore, many questions
of interest in understanding the effects of prophylactic vaccines concern postinfection
outcomes, such as severe disease, death, or transmission to others. As early as 1939, Kendrick
and Eldering described less severe disease in children inoculated with pertussis vaccine. More
recently, Préziosi and Halloran (2003a) estimated the beneficial effects of pertussis vaccination
on reducing transmission to others (see also Halloran, Préziosi, and Chu 2003) and preventing
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severe disease (Préziosi and Halloran 2003b) in breakthrough cases. Individuals with varicella
(chickenpox) vaccination also develop less severe disease (Vazquez et al. 2001). Assessing
candidate human immunodeficiency virus (HIV) vaccine effects on progression to AIDS
through both clinical and surrogate postinfection endpoints (Gilbert, Bosch, and Hudgens
2003a) as well as on transmission (Longini, Datta, and Halloran 1996) is crucial for evaluating
their potential public health benefit.
Two main approaches are currently used for estimating postinfection effects of vaccines. The
first approach includes all individuals under study, whether they become infected or not; the
second includes only the individuals who become infected. The first approach enjoys the
statistical validity associated with an intent-to-treat (ITT) analysis and provides an assessment
of the overall benefit of vaccination. However, such an approach does not distinguish vaccine
effects on susceptibility to infection from effects on the postinfection endpoints of interest.
Also, it may be less sensitive in detecting postinfection vaccine effects than an analysis that
conditions on infection. The second approach conditions on infection to estimate a net effect
of the vaccine on the postinfection endpoint in just those people who become infected.
However, conditioning on an event, such as infection, that occurs subsequent to receipt of
vaccine or control may result in selection bias (Halloran and Struchiner 1995). Because the set
of individuals who would become infected if vaccinated is likely not identical to the set of
those who would become infected if given control, comparisons that condition on infection do
not have a causal interpretation (Frangakis and Rubin 2002). For example, a vaccine might
protect only people with strong immune systems, so that infected vaccinees tend to have weaker
immune systems on average compared with infected controls. As a result, infected vaccinees
could have worse postinfection outcomes on average than the infected controls due solely to
selection bias. The resulting false conclusion that vaccination is harmful with respect to
postinfection outcomes could result in the discarding of a potentially useful vaccine candidate
(Hudgens, Hoering, and Self 2003; Gilbert et al. 2003a).
As a first motivating example, Préziosi and Halloran (2003b) analyzed data from a pertussis
vaccine field study in Niakhar, Senegal from January 1 to December 31, 1993, in children age
6 months through 8 years. During that one calendar year, there were 3,845 and 1,020 person-
years at risk in the vaccinated and unvaccinated children (M.-P. Préziosi, personal
communication). Of 548 cases in the vaccinated group, 176 were severe, and of 206 cases in
the unvaccinated group, 129 were severe. Préziosi and Halloran (2003b) defined an estimator
of vaccine efficacy against severe disease conditional on being infected and having disease as
(1)
The analysis yields , 95% confidence interval (CI) = (.40, .56).
Vesikari, Rautanen, Varis, Beards, and Kapikian (1990) provided a second motivating example
in their analysis of a randomized, double-blinded, placebo-controlled trial of a Rhesus rotavirus
candidate vaccine. The trial was conducted in children age 2–5 months in 1985–1987 in
Finland, with 100 children randomized to each arm. The effect of the vaccine on the clinical
course of infection was considered by comparing severity (mild, moderate, or severe) between
vaccinees and placebotreated individuals with confirmed Rotavirus diarrhea using Fisher’s
exact test. If severe and moderately severe cases were combined, then the foregoing approach
of Préziosi and Halloran could also be used. In particular, of 10 cases in the vaccinated group,
5 were severe or moderately severe, and of 16 cases in the placebo group, 13 were severe or
moderately severe, such that, using (1), we have , 95% CI=(-.11,.74).
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At first glance, both vaccines seem to be protective against severe disease. However, due to
the possibility of selection bias, we cannot be sure of this without further investigation.
Different methods are used to adjust analyses for posttreatment variables, such as infection
(Robins and Greenland 1992,1994;Rosenbaum 1984). Our approach is based on an extension
of the potential outcomes framework for estimating causal effects (Rubin 1978;Holland
1986). In particular, Frangakis and Rubin (2002) and Rubin (2000) proposed a method to adjust
for posttreatment variables, called principal stratification, that stratifies on the joint potential
posttreatment variables (e.g., infection) under each treatment being considered. The causal
effects of one treatment compared with the other on a main outcome of interest (e.g., disease
severity) are defined within these principal strata and are called principal effects. In studying
HIV vaccines, Hudgens et al. (2003) and Gilbert et al. (2003b) adopted the principal
stratification approach to assess HIV vaccine effects on the continuous postinfection outcome
viral load in the principal stratum of individuals who would be infected under vaccine and
placebo. However, they focused on testing, and did not consider binary postinfection endpoints.
In this article we use a similar approach, but in contrast to the previous work, here we use
principal stratification to define causal vaccine effects on binary postinfection endpoints and
focus on estimation and identifiability. We also analyze data from two actual vaccine studies.
In Section 2 we formally define the estimands, particularly the causal estimand of interest and
two currently used estimands for vaccine effects on postinfection outcomes, and state our three
main assumptions of stable unit treatment value (SUTVA), independence, and monotonicity.
In Section 3 we show the causal estimand to be not identifiable without further assumptions
regarding the selective mechanism of the vaccine. In Section 4 we developed a variety of
selection models that identify the causal estimand. We then derive closedform maximum
likelihood estimators (MLEs) under several of these models, including the models that assume
maximum possible levels of positive and negative selection bias. Using these approaches, we
analyze the rotavirus vaccine candidate and the pertussis vaccine studies.
2. DEFINING VACCINE EFFECTS
Consider a group of individuals, i = 1,…,n, each of whom potentially receives either vaccine
or placebo. Following the notation of Rubin (1990a) and similar to the development of Gilbert
et al. (2003b), let the vector Z = (Z1,…,Zn) denote the vector of treatment assignments for n
individuals with Zi = v if the ith individual is assigned vaccine and Zi = p if the ith individual
is assigned placebo or control. In this article assignment is assumed to be equivalent to receipt.
Denote the potential infection outcome of the ith individual if the study group were assigned
Z as Si(Z), where Si(Z) = 0 if uninfected and Si(Z) 1 if infected. Then S(Z) is the n-vector of
potential infection outcomes if the assignment vector were Z. For simplicity, we suppress the
dependence on Z by letting S = S(Z). The focus of this work is on evaluating the causal effect
of vaccine on a binary outcome Y that occurs after an individual becomes infected, such as
transmission to another individual, severe disease, or death. Formally, if Si(Z) = 1, then we
define the potential postinfection outcome Yi(Z, S) 1 if the ith individual would have the worse
(i.e., more severe) postinfection outcome of interest given (Z, S), and Yi(Z, S) = 0 otherwise.
If an individual’s potential infection outcome for an assignment is uninfected [i.e., Si(Z) = 0],
then Yi(Z, S) is undefined and denoted by *.
We assume that the potential outcomes for each individual i are independent of the treatment
assignment of other individuals. This assumption, known also as the assumption of no
interference between units (Cox 1958), is obviously violated in many infectious disease settings
(Rubin 1978,1990a;Halloran and Struchiner 1995); however, we make it to clarify the problem
in its simplest form. We also assume there are only two possible infection outcomes and, at
most, two possible postinfection outcomes. These two assumptions are expressed formally as
follows.
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Stable unit treatment value assumption (SUTVA) (Rubin 1978; Angrist, Imbens, and Rubin
1996). For any two treatment assignments, Z = (Z1,…,Zn) and , the following
hold:
a. If , then Si(Z) = Si(Z′).
b. If  and , then Yi(Z,S) = Yi(Z′, S′).
The SUTVA assumption allows us to write Si(Zi) and Yi(Zi, Si(Zi)) rather than Si(Z) and Yi(Z,
S). Under SUTVA,  whenever , so we can write Yi(Zi) instead of Yi(Zi,
Si(Zi)). Finally, we let  denote the observed infection outcome Si(v) or Si(p), depending on
treatment assignment, and analogously,  for the observed postinfection outcome.
We define a basic principal stratification, P0, according to the joint potential infection
outcomes SP0 = (S(v), S(p)) (Frangakis and Rubin 2002). Table 1 summarizes the four basic
principal strata defined by the joint potential infection outcomes, (S(v), S(p)), and the strata
defined by the joint potential postinfection outcomes, (Y(v), Y(p)), within each principal
stratum. The four basic principal strata are composed of immune (not infected under both
vaccine and placebo), harmed (infected under vaccine but not placebo), protected (infected
under placebo but not vaccine), and doomed individuals (infected under both vaccine and
placebo). Because membership in a basic principal stratum is not affected by whether an
individual is actually assigned to vaccine or placebo, the strata can be used in the same way as
pretreatment covariates, with causal postinfection vaccine effects defined within a basic
principal stratum SP0.
In general, causal effects are defined in terms of potential outcomes. Table 1 shows that the
doomed basic principal stratum, SP0 = (1, 1), is the only stratum in which both potential
postinfection endpoints, and thus their joint distribution, are defined. For this reason, in our
setting, defining individual postinfection causal vaccine effects makes sense only in the
doomed basic principal stratum, SP0 = (1, 1). In other words, we can speak of a vaccine causing
an improvement or worsening of a postinfection outcome only for an individual who would
become infected whether vaccinated or not. Thus, following Rubin (2000), two population-
level causal estimands can be validly defined: (1) the effect of vaccine on infection (S) for all
participants, and (2) the effect of vaccine on the binary postinfection outcome (Y) for those
participants who would be infected under both treatment assignments.
To define the first causal estimand, the individual causal effect of vaccination on infection in
individual i might be expressed as a difference or ratio (Rubin 1990b),
(2)
Vaccine efficacy is typically expressed in terms of a relative risk difference, so that, similar to
Struchiner and Halloran (1996), we define the individual causal effect of vaccination on
infection as
(3)
with the convention VESi = 0 when Si(v) = Si(p) = 0. Recall that we assume there is perfect
compliance; that is, assignment to vaccine (control) is equivalent to receipt of vaccine (control).
Without this assumption, (2) and (3) would be causal effects of assignment to vaccine. The
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ramifications of noncompliance on the assessment of causal vaccine effects are not considered
here.
Because for any individual at least one potential outcome is always unobserved, the individual
causal effect of vaccine on infection cannot be observed. Therefore, one must rely on contrasts
between different individuals to estimate average or population-level causal effects (Holland
1986). Given the individual causal effect (3), similar to Struchiner and Halloran (1996) and
Gilbert et al. (2003b), we define the corresponding population causal vaccine effect by
We call this the relative average causal effect (RACE) of vaccination on infection. Because S
(v) and S(p) are binary, the expectations can be replaced by probabilities, and VES can be
interpreted as the relative reduction in the probability of infection given vaccine compared with
control.
Estimation of population average causal effects requires specification of the assignment
mechanism (Rubin 1990b), that is, how the individuals were assigned to vaccine or placebo.
We assume that treatment assignment is independent of the potential outcomes.
Assumption 2
Z is independent of {Y(v), Y(p), S(v), S(p)}.
Here and in the sequel, Y(z) = * if S(z) = 0 for z = v, p. Randomization is one assignment
mechanism where the treatment assignment is independent of the potential outcomes. It now
follows
Next we define three estimands regarding the effect of vaccination on the postinfection
outcome Y. Usually, the notation VEI is used specifically for vaccine efficacy for
infectiousness, that is, the effect of vaccination on transmission to others (Halloran, Struchiner,
and Longini 1997), and VEP is used for vaccine efficacy for progression or severity as in (1).
Here we use VEI throughout the development to refer to vaccine efficacy for any binary
postinfection outcome. This enables us to use standard notation for the secondary attack rate
(SAR), the probability of transmission from an infected to a susceptible individual. In the
development that follows, SAR is defined more generally as the proportion of infected
individuals with the worse postinfection outcome.
One current approach to assessing vaccine effects on postinfection endpoints defines a net
vaccine effect estimand that conditions on infection, that is,
with the second equality following from Assumption 2. However, in general  does not
have a causal interpretation, because the set of individuals with S(v) = 1 is not necessarily
identical to the set of individuals with S(p) = 1 (Rosenbaum 1984; Frangakis and Rubin
2002).
Another current approach defines an estimand for the effect of vaccination on different levels
of severity of disease or mortality without conditioning on being infected. Such an estimand
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might be considered ITT, because it does not condition on the posttreatment variable Sobs; that
is, it incorporates all individuals according to their treatment assignment. An example of an
ITT estimand is
where we adopt the convention Y(z) × S(z) = 0 if S(z) = 0, z = v, p. This is a general form for
what Préziosi and Halloran (2003b) called “VES for severity.” Although  does have a
causal interpretation, it combines vaccine effects on susceptibility and postinfection outcome
as shown by the following relation:
We propose a third estimand for the effect of vaccination on a binary postinfection outcome
that has a causal interpretation and is separate from vaccine effects on susceptibility. To define
the causal VEI, we use the basic principal stratification shown in Table 1. In particular, the
individual causal vaccine effect on the postinfection outcomes is defined as
for individuals within the doomed principal stratum only. Following the development of
VES earlier, we define the population postinfection causal vaccine effect VEI within the
doomed principal stratum as
(4)
Like VES, (4) could equivalently be given in terms of probabilities, because the postinfection
random variables Y(v) and Y(p) are assumed to be binary, such that VEI can be interpreted as
the causal estimand measuring the relative reduction in the probability of the worse
postinfection outcome given vaccine compared with placebo in those individuals who would
be infected under either treatment assignment. The challenge in estimating principal effects
such as (4) lies in identifying those individuals in the doomed basic principal stratum, because
at most one potential infection outcome is ever observed for a particular individual. To help
overcome this obstacle, we make the following monotonicity assumption.
Assumption 3
Monotonicity. The individual causal effect of vaccination on infection is nonnegative; that is,
VESi ≥ 0 for all i.
Under this assumption, an individual who would become infected under vaccine also would
become infected under placebo, so the harmed principal stratum SP0 = (1, 0) is empty. In the
context of possible noncompliance with treatment assignment, Angrist et al. (1996) and Imbens
and Rubin (1997) made a monotonicity assumption akin to Assumption 3, which immediately
eliminates the basic principal stratum of defiers (persons who would always take the opposite
of their treatment assignment). By Assumption 3, we are not assuming that the individual
postinfection causal effect of vaccination is nonnegative; rather, we allow that vaccination
could have a negative (i.e., harmful) causal effect on the postinfection outcome. Indeed, one
of our goals is to identify the conditions under which it could be determined the postinfection
causal effect is negative.
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Under Assumption 3, for each possible observed combination of , we can deduce to
which basic principal stratum an individual must belong:
Thus the infected vaccine recipients will immediately provide information about the
distribution of the postinfection outcome Y(v) in the doomed principal stratum. However,
getting a handle on Y(p) in SP0 = (1, 1) is still problematic, because infected placebo recipients
may be members of either the protected or the doomed principal stratum. In Section 4 we derive
models that allow us to identify the distribution of Y(p) in the doomed principal stratum and,
in turn, the postinfection causal vaccine effect VEI given in (4).
3. IDENTIFIABILITY AND ESTIMATION OF VACCINE EFFECTS
In this section we investigate identifiability and estimation of the estimands defined in the
previous section under Assumptions 1–3 only.
3.1 Parameterization
Let the parameters θ govern the probabilities associated with the basic principal stratum. In
our case the stratum SP0 is empty, so let θ = (θ00, θ01, θ11), where
(5)
Next, let the parameters ϕ = (ϕ00, ϕ01, ϕ10, ϕ11) govern the probabilities associated with the
joint potential postinfection outcomes in the doomed basic principal stratum SP0 = (1, 1), where
(6)
Let the parameters γ = (γ0, γ1) govern the probabilities associated with the two possible potential
postinfection outcomes under placebo in the protected basic principal stratum, SP0 = (0, 1),
where
(7)
Finally, let the law of Z be given by Pr{Z=z; ψ}=ψz for z = v, p.
Under this parameterization, the causal estimand of vaccine efficacy for susceptibility is
Based on the definition of the causal estimand VEI given in (4), we are interested not in the
joint probabilities ϕkm(k,m=0,1), but rather in just two of the marginal probabilities. In
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Without further assumptions, VEI is not identifiable from the observable random variables
(Yobs, Sobs, Z). To see this, first write the probability function for the observable random
variables Pr[Z=z,Sobs=s,Yobs=y; θ, γ, ϕ ψ] as
(9)
where I(·) is the usual indicator function. Next, suppose that we have θ01 = θ11, ϕ.1=∊, and
γ1=1-∊ for ∊ ε ∈ (0,1). Then the probability function given in (9) is constant for different values
of ∊. Moreover, VEI =1-ϕ1./∊ depends on the choice of ∊, indicating that VEI is not identifiable.
In contrast, the estimands VES, , and  are identifiable without further assumptions.
3.3 Estimation
Suppose that we observe n independent and identically distributed realizations of (Z, Sobs,
Yobs), where Yobs is undefined or does not exist if Sobs = 0. There are six possible observed
combinations of (Z, Sobs, Yobs). Let nsy(z) be the number of each combination observed in the
study population, where s = 0, 1 is the observed infection outcome Sobs; y = 0, 1, * is the
observed postinfection outcome Yobs; and z = v, p. That is,
and
where the summations are over i = 1,…,, n. (Note that the double subscripts do not have the
same meaning for the n’s as for the ϕ’s and θ’s.) We assume each of the six combinations is
observed at least once, that is, nsy(z) > 0 for (s, y) = (0, *), (1, 0), (1, 1) and z = v, p. Let n(p)
= n0*(p) + n10(p) + n11(p) and n(v) = n0*(v) + n10(v) + n11(v) denote the number of individuals
assigned to placebo and to vaccine. Let n1.(p) = n10(p) + n11(p) and n1.(v) = n10(v) + n11(v)
denote the number of infected individuals assigned to placebo and vaccine. Let
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that is, ARz is the observed attack rate in the group assigned treatment z. Finally, let
that is, SARz is the observed secondary attack rate in the group infected given treatment z.
MLEs of the identifiable vaccine efficacy estimands can be found by maximizing the likelihood
subject to constraints on θ, γ, and ϕ that ensure that (5)–(7) are probability functions. Using
the results from the Appendix, it follows that the MLE of VES is given by
(10)






The causal estimand VEI is not identifiable because ϕ.1, the denominator of the right side of
(8), is not identifiable. But ϕ1., the numerator of the right side of (8), can be identified by the
observable random variables. The corresponding MLE is given by
(14)
that is, the observed secondary attack rate in the vaccine arm. Finally, although ϕ.1 is not
identifiable, we can identify
(15)
The MLE of (15) is SARp such that any feasible pair satisfying
(16)
is an MLE of (γ1, ϕ.1). In the following section we introduce selection models that identify
(γ1, ϕ.1). These models add an additional constraint to the parameters such that there is only
one feasible pair  that satisfies (16). Because the value of the likelihood remains the
same, we have the unique MLE of ϕ.1 and, therefore, VEI. Before proceeding, we revisit our
examples.
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3.4.1 Rotavirus Candidate Vaccine—In the rotavirus candidate vaccine study (Vesikari
et al. 1990), the observed data were
From (10),  – (10/100)/(16/100) = .375. It then follows from (13) that  – (5/100)/
(13/100) = .62. The secondary attack rates are  and SARp = 13/16 = .81,
such that  – (5/10)/(13/16) = .385.
To consider estimation of VEI, Table 2 shows the relation of the observed data to the basic
principal strata and the strata of joint potential postinfection outcomes within each basic
principal stratum. By Assumptions 1–3, we know the following:
• All n10(v) + n11(v) = 10 belong to the doomed stratum SP0 = (1, 1).
• All n0*(p) = 84 belong to the immune stratum SP0 = (0, 0).
• The n0*(v) = 90 could belong to SP0 = (0, 0) or SP0 = (0, 1).
• The n10(p) + n11(p) = 16 could belong to SP0 = (0, 1) or SP0 = (1, 1).
Ignoring statistical variability, by Assumption 2 (independence), because there are 10 vaccine
recipients in the doomed stratum, there are 10 placebo recipients in the doomed stratum as
well. Because there are 84 placebo recipients in the immune stratum, there are 84 vaccine
recipients in the immune stratum as well. Thus there must be 6 recipients from each of the
vaccinated and unvaccinated groups in the protected stratum. Thus we can estimate the size of
the unobserved principal stratum SP0 = (0, 1). However, we do not know which 6 of the 16
infected placebo recipients are in the protected stratum SP0 = (0, 1) or which 10 of the 16 are
in the doomed stratum SP0 = (1, 1). This illustrates the need for further assumptions to identify
VEI.
3.4.2 Pertussis Vaccine—The pertussis vaccine analysis of Préziosi and Halloran
(2003b) included exactly 1 year of follow-up (the calendar year 1993), so that the person-years
at risk are a close approximation to the number of persons at risk. Thus we use the person-
years at risk for n(v) and n(p). Although vaccine status was not randomized, there was no
evidence of systematic differences between the vaccinated and unvaccinated groups, indicating
that Assumption 2 (independence) might be reasonable. Active surveillance to find cases makes
it unlikely that ascertainment bias plays a role. (See Préziosi and Halloran 2003b for further
discussion.) The observed data are
From (10),  – (548/3,845)/(206/1,020) =.29. The secondary attack rates are
 and SARp = 129/206 = .63, such that  – (176/548)/(129/206)
= .49, which is the same as  given in (1). Finally  – (176/3,845)/(129/1,020) = .
64, which Préziosi and Halloran (2003b) called  for severity.
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4. SELECTION BIAS MODELS
In the previous section we showed that VEI is not identifiable under Assumptions 1–3 (SUTVA,
independence, and monotonicity). In particular, the parameterization (5)–(7) defines a family
of joint distribution functions of (Z, S(v), S(p), Y(v), Y(p)) for which the resulting conditional
distributions of Y(p)|SP0 = (1, 1) are not identified from the observable random variables (Z,
Sobs, Yobs). In this section we consider different additional assumptions about the selective
effect of the vaccine on susceptibility to infection that restrict inference to a subset of this
family such that the distribution of Y(p)|SP0 = (1, 1) and, in turn, VEI are identifiable. The lack
of identifiability of VEI derives from ϕ.1 and γ1 occurring in (9) only through the term
(17)
Thus for any fixed values of θ01, θ11, and Pr[Yobs = 1, Sobs = 1| Zobs = p], all pairs of parameters
(18)
will yield the same distribution of (Z, Sobs, Yobs). The selection models presented in this section
place additional constraints on the parameter space such that only one pair of parameters
satisfies (18). These selection models are nonparametric in the sense that no additional
restrictions are placed on the distribution of (Z, Sobs, Yobs) (Scharfstein, Rotnitzky, and Robins
1999). Although the observed data do not allow us to distinguish among selection models,
through sensitivity analyses we can estimate VEI under each selection model in a collection
of models that represent a range of plausible selective effects of vaccine. Moreover, if we can
show that VEI is significantly greater (less) than 0 over all values of possible selective effects,
the observed data provide sufficient evidence to conclude the vaccine has a positive (negative)
causal effect on the postinfection endpoint under Assumptions 1–3 only.
We begin in Section 4.1 by assuming there is no selective vaccine effect. In Section 4.2 we
present two extreme models that assume maximum possible levels of positive and negative
selection bias and, in turn, yield bounds on the MLE of the causal estimand in a fashion similar
to the approaches of Manski (1990), Balke and Pearl (1997), and Hudgens et al. (2003). In
Section 4.3 we present three approaches to sensitivity analysis that allow a range of selective
effects. We discuss making inferences on VEI accounting for statistical variability in Section
4.4, and then apply the different methods to the two vaccine examples in Section 4.5.
4.1 No Selection Bias
The simplest assumption is that there is no selection; that is, the probability of the postinfection
outcome conditional on infection under placebo is independent of infection status under
vaccine,
(19)
which implies ϕ.1 = γ1. It follows immediately that assumption (19) identifies VEI and, from
(16), that the resulting MLE is
(20)
From (14), (20), and the definition of VEI given by (8), it follows that the MLE of VEI equals
 as given in (11). In other words, under the additional assumption of no selection bias as
specified by (19), the MLE of the causal vaccine effect is the usual secondary attack rate ratio
estimator one obtained when conditioning on infection as in (1).
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4.2 Upper and Lower Bounds
In this section we present selection models that provide the largest and smallest estimators of
VEI. In particular, the upper bound selection model yields the parameter pair satisfying (18)
that has the largest ϕ.1 (and thus the largest VEI). Because (18) is simply the intersection of the
unit square and a line with negative slope, it follows that the pair with maximal ϕ.1 must be on




In words, the upper bound selection bias model assumes either that (a) all placebo recipients
in the doomed principal stratum have the worse postinfection outcome or (b) all placebo
recipients in the protected principal stratum have the better postinfection outcome. Under the
model assuming either (21) or (22), ϕ.1 is identifiable; the proof is not shown but is available
from the authors. From (16), it follows that the unique MLE of VEI assuming either (21) or
(22) is given by
(23)
All MLEs obtained under Assumptions 1–3 must be less than or equal to .
Similarly, the lower bound selection bias model assumes that under assignment to placebo, the
worse postinfection outcome occurs either with probability 0 in the doomed principal stratum,
(24)
or with probability 1 in the protected principal stratum,
(25)
This model renders ϕ.1 identifiable, and from (16) the resulting unique MLE of VEI is
(26)
In summary, even though VEI is not identifiable from the data at hand, these extreme selection
bias models provide bounds on the MLE. Moreover, we have derived the circumstances when
the upper bound will be negative (suggesting harm) and when the lower bound will be positive
(suggesting benefit). For example,  will be negative if and only if  and
. Similarly,  will be positive if and only if  and
. In contrast, for , we know
that  will be always positive and  will be always negative. In other words, for
large enough  we cannot determine the sign of VEI unless further assumptions are made
beyond SUTVA, independence, and monotonicity.
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Estimating the causal vaccine effect under an extreme degree of selection bias is useful in
bounding the estimate of the postinfection effect above and beyond any possible selective
effects. However, the true degree of selection bias is likely less than the foregoing extreme
models, such that using  or  may be too conservative. Therefore, we consider
classes of selection models that include the foregoing no selection and extreme models.
Through sensitivity analysis over a particular class, we can explore the relationship between
the assumed degree of selection bias and our inference about VEI. This approach allows for
potentially more realistic models and less conservative inference.
4.3.1 Log Odds Ratio of Infection—Our first approach is similar to that of Scharfstein et
al. (1999) and Robins, Rotnitzky, and Scharfstein (2000) and adapted by Gilbert et al.
(2003b). We define a sensitivity model in terms of the log odds ratio of having the severe
postinfection endpoint under placebo in the doomed versus protected principal strata,
(27)
For example, if exp(β) = 2, then doomed individuals have twice the odds of having the worse
postinfection outcome under placebo compared with protected individuals. In terms of our
parameterization, this implies that
(28)
For fixed β, we can solve (16) and (28) for ϕ.1 and, in turn, VEI. A sensitivity analysis can then
be performed by repeating this process over a range of different β’s.
The selection models given in Sections 4.1 and 4.2 are special cases of the class of logistic
selection models given by (27) when β = 0 (no selection), β → ∞ (upper bound), or β → —∞




Because (29) implies (21) and (30) implies (22), we recover the extreme upper selection bias
model. The relation among the log odds ratio, upper bound, and no selection models are
depicted graphically in Figure 1.
4.3.2 Conditioning on γ1 as the Sensitivity Analysis Parameter—Section 4.3.1
posits a relation between the distributions of the postinfection endpoint under placebo in the
doomed and protected strata. Alternatively, we might simply condition on the nuisance
parameter γ1, which governs the postinfection endpoint distribution in the protected stratum.
Assuming that γ1 is known renders ϕ.1 and, hence, VEI identifiable. From (16), the resulting
MLE of VEI is
(31)
where γ1 varies between
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with the left side of (32) giving rise to  and the right side of (32) giving rise to
.
4.3.3 Complete-Data Model—A third approach to sensitivity analysis regards the unknown
basic principal stratum membership of the infected placebo recipients as missing data and
formulates the sensitivity analysis in terms of the complete-data likelihood. The observed data
are n10(p) and n11(p). If we could know the basic principal stratum membership, then the
complete data would be  and , the number of infected placebo recipients in the
doomed stratum with Y(p) 0 and Y(p) = 1, and  and , the corresponding number
in the protected stratum. Given the complete data, ϕ.1 becomes identifiable. The complete-data
log-likelihood for (θ, ϕ, γ) is given by
(33)
which factors in terms of θ, ϕ, and γ, say l(θ), l(ϕ), and l(γ). Maximizing l(ϕ) yields the same
MLE  as before. It also yields the MLE
(34)
the secondary attack rate under placebo in the doomed stratum. The sensitivity analysis
involves estimating VEI using (34) for all possible complete-data configurations consistent
with the assumptions and the constraints implied by the observed data. Molenberghs, Kenward,
and Goetghebeur (2001) called this set of point estimates the region of ignorance, and called
the collection of CIs or other measures of precision together with the region of ignorance the
region of uncertainty.
4.4 Statistical Variability
Once we assume a particular selection model, we have a finite-dimensional parametric
inference problem with a unique MLE. Therefore, conditional on a selection model, we use
standard methods to obtain CI estimates for VEI. For example, CIs can be computed assuming
the usual chi-squared limiting distribution of the profile likelihood ratio (Barndorff-Nielsen
and Cox 1994). Alternatively, using the observed information and the delta method, Wald-type
CIs for VEI can be determined. The resulting CIs can then be used to determine a region of
uncertainty for any of the sensitivity analyses described earlier. A region of uncertainty that
excludes 0 will then imply a statistically significant postinfection causal effect of the vaccine.
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4.5.1 Rotavirus Candidate Vaccine—For these data, , so from (23),
. In contrast, , so, from (26),
Figure 2(a) shows the sensitivity analysis of  as a function of the odds ratio eβ as described
in Section 4.3.1. Figure 3(a) shows the sensitivity analysis of  as a function of γ1 as described
in Section 4.3.2. From (32), the range for γ1 is [.5, 1.0 in this example. For these figures, profile
likelihood–based CIs are presented; Wald-type CIs gave qualitatively similar results. The
vertical dotted line in Figures 2 and 3 corresponds to the assumption of no selection bias. In
particular, in Figure 3,  corresponds to the MLE of γ1 under the assumption of no selection
bias.
Table 3 gives all possible configurations of the complete data for the placebo arm consistent
with the observed data and Assumptions 1–3 as described in Section 4.3.3. On the one hand,
the complete data are constrained by the observed data to satisfy 
and . On the other hand, Assumptions 1–3 imply that of the total of
16 infected placebo recipients, 6 must be in the protected stratum and 10 must be in the doomed
stratum. There are only four complete-data configurations that satisfy these constraints. These
four configurations can be envisaged by assigning the three infected placebo recipients with
mild infection to either the doomed stratum or the protected stratum. At one extreme, the three
are all in the doomed stratum; at the other extreme, they are all in the protected stratum. The
resulting four MLEs of VEI given in the bottom row of Table 3 compare the region of ignorance.
For this dataset, the assumption of no selection bias does not correspond to any possible
complete-data configuration. But the extreme lower and upper bound estimates,  and
, are included in the region of ignorance.
This example demonstrates the utility of the sensitivity analyses. For these data, the 95% CI
for VEI covers 0 for the lower bound selection model, indicating that one cannot conclude that
the vaccine has a protective causal effect against severe disease at the α = .05 level. In contrast,
the upper bound selection model CI excludes 0, indicating a significant protective effect. In
this situation, sensitivity analyses can be used to assess at what point significance is attained.
For example, Figures 2(a) and 3(a) indicate that even under the assumption of no selection
bias, the effect remains nonsignificant.
Finally, the lack of statistical significance in this example may be attributed simply to small
sample size. For instance, had the study been such that there were 1,000/arm with the same
observed marginal distributions (i.e., 3% mild and 13% severe in the placebo arm, 5% mild
and 5% severe in the vaccine arm), then the 95% CI for VEI under the lower bound model
would have been [.09,.46], indicating a significant causal vaccine effect on rotavirus disease
severity in individuals who would be infected regardless of vaccination status.
4.5.2 Pertussis Vaccine—For these data, , so from (23),
. In contrast, , so from (26), . Figures 2(b) and
3(b) show the sensitivity analyses of  as described in Sections 4.3.1 and 4.3.2. In both
figures, the lower limits of the 95% CIs are well above 0 over the range of both selection
models, suggesting that pertussis vaccination causes significant protection against severe
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disease in children who would develop pertussis regardless of vaccination. The sensitivity
analysis using the complete-data likelihood would proceed similarly as for the rotavirus vaccine
candidate, with many more possible data configurations and taking the unequal sizes of the
vaccinated and unvaccinated arms into account.
5. DISCUSSION
For vaccine studies in which the effect of vaccination on binary postinfection outcomes is of
interest, our results will enable researchers to quantify the soundness and limitations of their
findings. Combining principal stratification with a maximum likelihood approach, we have
developed methods for estimating the causal effect of vaccination on postinfection outcomes
in those individuals who would be infected under vaccine and placebo. Closed forms for the
MLE of the causal estimand have been derived assuming extreme upper, extreme lower, and
no selection bias models. These results indicate specific assumptions under which currently
used efficacy estimators have a causal interpretation; for example, the usual net postinfection
efficacy estimator is the MLE of our causal estimand under the assumption of no selection
bias. In contrast, the usual intent-to-treat estimator provides an upper bound on the
postinfection causal vaccine effect when the protective effect of the vaccine against infection
is not too large (i.e., ). We have also presented three approaches to
sensitivity analysis that allow selection models to range from no selection to the extreme
maximum possible levels. Coupled with confidence intervals, these sensitivity analyses
provide a comprehensive description of the uncertainty regarding VEI. For example, in the
analysis of the pertussis vaccine study, the estimated postinfection vaccine effect was
significantly greater than 0 for all selection bias models, including the extreme lower bound
model, indicating a significant causal effect in reducing disease severity. In other words, under
only the standard assumptions of SUTVA, monotonicity, and independence of treatment
assignment, we have shown that there is a definitive causal vaccine effect on severity of
pertussis in individuals who would be infected whether vaccinated or not.
Several extensions of this work and avenues for further research merit mention. For instance,
further research is needed on the consequences of relaxing several key assumptions. Regarding
Assumption 1, SUTVA is clearly violated in many vaccine field studies (Rubin 1990a; Halloran
and Struchiner 1995). When SUTVA is violated, an individual can have different potential
infection outcomes under the same treatment assignment. Therefore, defining the basic
principal stratum for an individual needs to account for the possible treatment assignments of
other individuals. Assumption 2 (independence) clearly holds in the rotavirus example because
the trial was randomized, and likely also holds in the pertussis field study, as discussed in
Section 3.4.2. In general, the effect of nonrandom allocation of the vaccine can be explored
through additional sensitivity analyses and other approaches for observational studies
(Rosenbaum 1995). In addition, exclusion restrictions not considered here may be necessary
if the independence assumption is not made. Assumption 3 (monotonicity) also likely holds
for the rotavirus and pertussis examples, because  in both studies. Relaxing
Assumption 3 to allow for a harmful vaccine effect on infection would make identifiability and
estimation of the postinfection causal estimand VEI more difficult. However, a vaccine that
increases susceptibility to infection would be unacceptable from a public health standpoint, so
that concerns about postinfection selection bias become less relevant. Finally, we have assumed
that assignment to a treatment is equivalent to receipt of that treatment. The increased
complexity of defining, identifying, and estimating causal effects in the presence of
noncompliance (Angrist et al. 1996) would likely necessitate further exclusion restriction
assumptions (e.g., given the actual treatment received, assignment to treatment carries no
additional information).
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Additional research is also needed to incorporate baseline covariates and allow for missing or
mismeasured infection or postinfection outcomes. The operating characteristics of conditional
and unconditional (i.e., ITT) tests for binary postinfection vaccine effects remain unknown.
Our preliminary comparisons (results not shown) suggest a conditional approach [similar to
that of Hudgens et al. (2003)] may be more powerful. These results are consistent with the
findings of Mehrotra, Li, and Gilbert (2005). Finally, as pointed out by a reviewer, the
multivariate literature on characterizing the set of possible joint distributions given fixed
marginal or conditional distributions (see, e.g., Joe 1997) may have direct application in the
principal stratification setting.
Correct assessment of vaccine effects on postinfection endpoints has important public health
consequences. For example, there is precedent and concern for vaccine-induced immune
responses causing disease enhancement (Kliks, Nisalak, Brandt, Wahl, and Burke 1989; Burke
1992; Mascola et al. 1993; Nabel 2001). If the estimated net postinfection vaccine effect
suggested a possible harmful effect, then a vaccine could be wrongfully discounted if, in fact,
the apparent negative effect were due to selection bias. Our methods could be used to determine
whether such an observed effect was consistent with selection bias. In contrast, if the estimated
net vaccine effect were positive, then one might be less compelled to distinguish (a) a selective
effect of the vaccine on infection from (b) the causal effect of the vaccine in the doomed
principal stratum, because either effect is beneficial from a public health perspective.
Disentangling (a) from (b) could be quite valuable from a scientific standpoint, however. For
example, our analysis of the pertussis vaccine study provides evidence that vaccination has an
effect on disease severity above and beyond that attributable to selection bias, suggesting the
vaccine produces an immune response that directly hinders severe symptoms, such as
paroxysms with whoops. This could suggest directions for further biological research. Another
example arises in HIV, where researchers are considering both antibody and T-cell–based
vaccines (McMichael, Mwau, and Hanke 2002; Nabel 2001) under the hypothesis that the
former will protect from infection and the latter will protect from disease or death. If a
combination vaccine proves effective in reducing the risk of morbidity or mortality, then
researchers will be interested in understanding the mechanism of protection, that is, to which
vaccine component is such an effect attributable. Analysis revealing a signifi-cant post-
infection causal vaccine effect in the doomed stratum would provide evidence of T-cell–based
protection. Separating (a) and (b) also might be helpful in predicting the success of particular
vaccination programs (Hayes, Alexander, Bennett, and Cousens 2000).
Although in this article we have handled the postinfection outcomes of transmission and disease
severity or death similarly, there are important differences. In particular, vaccine efficacy for
infectiousness (VEI) involves transmission to another susceptible individual, whereas vaccine
efficacy for severity or progression (VEP) involves only the infected individual. Thus, unlike
VEP, VEI can depend on the characteristics of the individuals susceptible to secondary
infection, as well as on the type of contacts between individuals. Also, an infected individual
could expose more than one individual, so that there could be several potential postinfection
outcomes, one for each exposed individual; for example, the study be in Préziosi and Halloran
(2003a), more than 20 individuals were exposed to one infected individual in some cases.
Alternatively, an infected individual may expose no other susceptibles, and then the potential
postinfection outcome would be undefined. Our method needs to be extended to such multiple
outcomes and possible dependencies.
In most vaccine studies in humans, whether or not an individual becomes infected is not under
the control of the investigator. The potential postinfection outcomes for individuals who would
not become infected under either vaccine or placebo are undefined, or are a priori counterfactual
(Frangakis and Rubin 2002), resulting in our defining the postinfection causal estimand in the
doomed stratum only. However, there are a few infectious agents that can be used in infection-
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challenge studies in either human or animal. For these types of studies, a more appropriate
approach might be that of Robins and Greenland (1992, 1994), which assumes that the
posttreatment variable is controllable; that is, the investigator can force the individuals to take
on any possible value of the posttreatment variable. Comparison of the different approaches
merits further research.
Acknowledgements
This work was supported in part by National Institutes of Health grants R37-AI29168, R01-AI054165, and R01-
AI32042. Halloran was also a visiting faculty member in the Statistics Division, Los Alamos National Laboratories.
The authors thanks Peter Gilbert, Andrew Hill, Marie-Pierre Préziosi, and Bryan Shepherd for helpful discussions.
APPENDIX: MAXIMUM LIKELIHOOD ESTIMATION
Let ξ = θ01γ1 + θ11ϕ.1 and consider maximizing the log-likelihood,
subject to the constraints
The maximum of ϕ1. is given by , such that we are left with the simpler
problem of maximizing
subject to (A.1)–(A.3).
The function 1(θ,ξ) is strictly concave over the closed, convex parameter space defined by (A.
1)–(A.3) such that a unique MLE exists and the (first-order) Kuhn–Tucker conditions are
necessary and sufficient for optimality (Fletcher 1987). In particular, define Lagrange
multipliers λ0,λ1,…,λ5 and Lagrangian function
where the summation is over i, j = 0, 1 such that i≤j. Then  is an MLE iff it is a feasible
point according to (A.1)–(A.3) and satisfies
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Under the assumption nsy(z) > 0 for all possible combinations of s, y, and z, we must have
, and  strictly greater than 0 to maximize l(θ, ξ), such that λ1 = λ3 = λ4 = 0. Similarly,
we must also have , such that λ5 = 0. Multiplying (A.5) and (A.6) by θij and ξ and
summing,
can be shown to yield λ0 = n. It follows that  is an MLE iff it satisfies (A.1)–(A.3) and
and
We can show the MLE of θ has the following closed form that depends on the data. In particular,
if
then the MLEs are given by
and
Otherwise,
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In either case, the MLE of ξ is given by
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Graphical Depiction of Selection Bias Models Described in Section 4. The four dotted curves
depict the log odds ratio selection model for β = 0, 1, 2, 4. The β = 0 model is equivalent to the
no selection model. The thick black lines on the edge of the unit square correspond to the upper-
bound selection model. The solid thin line with negative slope represents an example of a
family of joint distribution functions of (Z, S(v), S(p), Y(v), Y(p)) for which all combinations
of parameters (ϕ.1, γ1) on this line give rise to the same distribution of the observable random
variables (Z, Sobs,Yobs). Each selection model identifies exactly one pair of parameters (ϕ.1,
γ1) from this family, rendering VEI = 1 − ϕ1./ϕ.1 identifiable.
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Sensitivity Analysis Using the Odds Ratio of Having the Severe Postinfection Endpoint Under
Placebo in the Doomed versus Protected Principal Strata as Described in Section 4.3.1. (a)
Rotavirus; (b) pertussis. The vertical dotted line corresponds to the assumption of no selection
bias.
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Sensitivity Analysis Assuming γ1 = Pr{Y(p) = 1|SP0 = (0, 1); γ} Is Known as Described in
Section 4.3.2. (a) Rotavirus; (b) pertussis. The vertical dotted line gives the MLE of γ1 under
the assumption of no selection bias.
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Table 1
Basic Principal Stratification P0 Based on the Potential Infection Outcomes (S(v), S(p)) With Potential Postinfection
Strata Based on (Y(v), Y(p))











(Y(v), Y(p)) Postinfection interpretation
Immune (0, 0) (*, *) Always undefined
Harmed (1, 0) (0, *) Not severe vaccine, undefined placebo
(1, *) Severe vaccine, undefined placebo
Protected (0, 1) (*, 0) Undefined vaccine, not severe placebo
(*, 1) Undefined vaccine, severe placebo
Doomed (1, 1) (0, 0) Never severe
(1, 0) Harmed by vaccine
(0, 1) Helped by vaccine
(1, 1) Always severe
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